# RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma

> **NCT01189240** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 13 (actual)

## Conditions studied

- Adult Anaplastic Astrocytoma
- Adult Anaplastic Oligodendroglioma
- Adult Giant Cell Glioblastoma
- Adult Glioblastoma
- Adult Gliosarcoma
- Recurrent Adult Brain Tumor

## Interventions

- **DRUG:** gamma-secretase/Notch signalling pathway inhibitor RO4929097
- **BIOLOGICAL:** bevacizumab
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT01189240
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-12
- **Primary completion:** 2013-01
- **Final completion:** 2015-02
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Company decided to stop development of drug - 7/31/12
- **Last updated:** 2015-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01189240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01189240, "RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01189240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*